Carsten Holzmann


Affiliation: Universitaetzmedizin Rostock
Location: Rostock, Germany


  1. Holzmann C, Dräger D, Mix E, Hawlitschka A, Antipova V, Benecke R, et al. Effects of intrastriatal botulinum neurotoxin A on the behavior of Wistar rats. Behav Brain Res. 2012;234:107-16 pubmed publisher
  2. request reprint
    Holzmann C, Schmidt T, Thiel G, Epplen J, Riess O. Functional characterization of the human Huntington's disease gene promoter. Brain Res Mol Brain Res. 2001;92:85-97 pubmed
    ..Binding affinities of DNA-protein interactions were defined by electrophoretic mobility shift assays and the protected nucleotide positions were determined by DNase I footprinting. ..
  3. Nguyen H, Metzger S, Holzmann C, Koczan D, Thiesen H, von Horsten S, et al. Age-dependent gene expression profile and protein expression in a transgenic rat model of Huntington's disease. Proteomics Clin Appl. 2008;2:1638-50 pubmed publisher
  4. request reprint
    Ubl A, Berg D, Holzmann C, Kruger R, Berger K, Arzberger T, et al. 14-3-3 protein is a component of Lewy bodies in Parkinson's disease-mutation analysis and association studies of 14-3-3 eta. Brain Res Mol Brain Res. 2002;108:33-9 pubmed
    ..In accordance with these findings, there was no staining of substantia nigra Lewy bodies with antibodies specific for the 14-3-3 eta subunit. ..
  5. Boy J, Schmidt T, Schumann U, Grasshoff U, Unser S, Holzmann C, et al. A transgenic mouse model of spinocerebellar ataxia type 3 resembling late disease onset and gender-specific instability of CAG repeats. Neurobiol Dis. 2010;37:284-93 pubmed publisher
    ..Few and small intranuclear aggregates appeared first at the age of 18 months, further supporting the claim that neuronal dysfunction precedes the formation of intranuclear aggregates...
  6. request reprint
    von Horsten S, Schmitt I, Nguyen H, Holzmann C, Schmidt T, Walther T, et al. Transgenic rat model of Huntington's disease. Hum Mol Genet. 2003;12:617-24 pubmed
    ..This model allows longitudinal in vivo imaging studies and is therefore ideally suited for the evaluation of novel therapeutic approaches such as neurotransplantation. ..
  7. Boy J, Schmidt T, Wolburg H, Mack A, Nuber S, Böttcher M, et al. Reversibility of symptoms in a conditional mouse model of spinocerebellar ataxia type 3. Hum Mol Genet. 2009;18:4282-95 pubmed publisher
  8. request reprint
    Berg D, Holzmann C, Riess O. 14-3-3 proteins in the nervous system. Nat Rev Neurosci. 2003;4:752-62 pubmed
  9. request reprint
    Hering R, Petrovic S, Mietz E, Holzmann C, Berg D, Bauer P, et al. Extended mutation analysis and association studies of Nurr1 (NR4A2) in Parkinson disease. Neurology. 2004;62:1231-2 pubmed

More Information


  1. Nuber S, Petrasch Parwez E, Winner B, Winkler J, von Horsten S, Schmidt T, et al. Neurodegeneration and motor dysfunction in a conditional model of Parkinson's disease. J Neurosci. 2008;28:2471-84 pubmed publisher
    ..Furthermore, alpha-syn-associated cytotoxicity is independent of filamentous inclusion body formation in our conditional mouse model. ..
  2. request reprint
    Nguyen H, Kobbe P, Rahne H, Wörpel T, Jäger B, Stephan M, et al. Behavioral abnormalities precede neuropathological markers in rats transgenic for Huntington's disease. Hum Mol Genet. 2006;15:3177-94 pubmed
    ..The dissociation of onset between behavioral and neuropathological markers is suggestive of as yet undetected processes, which contribute to the early phenotype of these HD transgenic rats. ..
  3. request reprint
    Boy J, Leergaard T, Schmidt T, Odeh F, Bichelmeier U, Nuber S, et al. Expression mapping of tetracycline-responsive prion protein promoter: digital atlasing for generating cell-specific disease models. Neuroimage. 2006;33:449-62 pubmed
    ..The study serves as a precursor for a database resource allowing evaluation of the suitability of different promoter mouse lines for generating disease models. ..
  4. Holzmann C, Mäueler W, Petersohn D, Schmidt T, Thiel G, Epplen J, et al. Isolation and characterization of the rat huntingtin promoter. Biochem J. 1998;336 ( Pt 1):227-34 pubmed
    ..DNase I footprinting and electrophoretic mobility-shift assays were used to define the nucleotide positions and binding affinity of DNA-protein interactions. ..
  5. request reprint
    Kántor O, Temel Y, Holzmann C, Raber K, Nguyen H, Cao C, et al. Selective striatal neuron loss and alterations in behavior correlate with impaired striatal function in Huntington's disease transgenic rats. Neurobiol Dis. 2006;22:538-47 pubmed
    ..No alterations in mean total numbers of striatal neurons were found in 6-month-old animals. Testing 14-month-old animals in a choice reaction time task indicated impaired striatal function of tgHD rats compared with controls. ..
  6. request reprint
    Bauer A, Zilles K, Matusch A, Holzmann C, Riess O, von Horsten S. Regional and subtype selective changes of neurotransmitter receptor density in a rat transgenic for the Huntington's disease mutation. J Neurochem. 2005;94:639-50 pubmed
    ..In particular, there is evidence for a contribution of predominantly presynaptically localized cholinergic and noradrenergic receptors in the response to Huntington's disease pathology. ..
  7. request reprint
    Marx F, Holzmann C, Strauss K, Li L, Eberhardt O, Gerhardt E, et al. Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet. 2003;12:1223-31 pubmed
  8. request reprint
    Holzmann C, Kruger R, Saecker A, Schmitt I, Schols L, Berger K, et al. Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease. J Neural Transm (Vienna). 2003;110:67-76 pubmed
    ..Although the -668C/-116G haplotype was more common in PD patients, this difference was not significant. ..
  9. request reprint
    Rahner N, Holzmann C, Kruger R, Schols L, Berger K, Riess O. Neurofilament L gene is not a genetic factor of sporadic and familial Parkinson's disease. Brain Res. 2002;951:82-6 pubmed
    ..Association studies based on these haplotypes revealed no significant differences between PD patients and 344 control individuals. Therefore, NF-L is unlikely to play a major role in the pathogenesis of PD. ..
  10. Holzmann C, Saecker A, Epplen J, Riess O. Avoiding errors in the diagnosis of (CAG)n expansion in the huntingtin gene. J Med Genet. 1997;34:264 pubmed
  11. Hawlitschka A, Holzmann C, Wree A, Antipova V. Repeated Intrastriatal Botulinum Neurotoxin-A Injection in Hemiparkinsonian Rats Increased the Beneficial Effect on Rotational Behavior. Toxins (Basel). 2018;10: pubmed publisher
    ..The data give evidence for the possibility of repeated intrastriatal administrations of BoNT-A, for treatment of motor symptoms in experimental hemi-PD over a longer time. ..
  12. Antipova V, Wree A, Holzmann C, Mann T, Palomero Gallagher N, Zilles K, et al. Unilateral Botulinum Neurotoxin-A Injection into the Striatum of C57BL/6 Mice Leads to a Different Motor Behavior Compared with Rats. Toxins (Basel). 2018;10: pubmed publisher
  13. Schlegel V, Thieme M, Holzmann C, Witt M, Grittner U, Rolfs A, et al. Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice. Int J Mol Sci. 2016;17: pubmed
    ..Our results suggest that allopregnanolone/cyclodextrin ameliorate most side effects of miglustat in wild-type mice. ..
  14. Meyer A, Wree A, Günther R, Holzmann C, Schmitt O, Rolfs A, et al. Increased Regenerative Capacity of the Olfactory Epithelium in Niemann-Pick Disease Type C1. Int J Mol Sci. 2017;18: pubmed publisher
    ..Interestingly, we also observed therapy-induced alterations in treated NPC1+/+ controls. Thus, olfactory testing may provide useful information to monitor pharmacologic treatment approaches in human NPC1. ..